|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our data indicate a novel role of eIF3e/Int6 in the regulation of EMT in breast epithelial cells and support a tumor suppressor role of eIF3e/Int6.
|
22907435 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Loss of heterozyosity (LOH) was detected in 11 of 39 (28%) of the tumor samples informative for a polymorphic sequence in intron 7 of INT6.
|
9403073 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of fatty acid binding protein 5 (FABP5), poly(A) binding protein cytoplasmic 1 (PABPC1), DEAD box polypeptide 5 (DDX5), splicing factor 3b subunit 1 (SF3B1), murine mammary tumour integration site 6 (EIF3S6), tropomyosin 2β (TPM2), transgelin (TAGLN) and cyclin-dependent kinase-associated protein (Cks2) genes was measured in bladder samples using real-time reverse transcription-polymerase chain reaction.
|
21672358 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Only 4% of WapInt6sh non-breeding females developed tumors by 2 years of age.
|
17626637 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The high expression of eIF3e in colon cancer was significantly correlated with tumor size (P < 0.001), lymph node involvement (P < 0.001), distant metastasis (P < 0.001), clinical stage (P < 0.001), histopathologic classification (P < 0.001), and vessel invasion (P = 0.036).
|
25400724 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To address this discrepancy and identify HIF-2 alpha-specific target genes, we performed yeast two-hybrid analysis and identified the tumor suppressor Int6/eIF3e/p48 as a novel target gene product involved in HIF-2 alpha regulation.
|
17324924 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In 85% of the tumors with reduced Int6 expression, the transcription promoter and first exon were hypermethylated, whereas only 4% of the tumors with elevated Int6 RNA levels were hypermethylated (P <0.000001).
|
15867213 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the current study, we investigate the role of the tumor suppressor Int6/eIF3e in the regulation of the expression of angiogenic factors in neuronal cells.
|
22960363 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additional studies on larger series of tumor specimens with long-term follow-up are needed to determine whether Int-6/eIF3-p48 expression may represent a new prognostic or predictive marker.
|
11115556 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, EIF2S6/Int-6, which was originally identified as a common integration site for the mouse mammary tumour virus in virally induced mouse mammary tumours, is a candidate breast cancer susceptibility gene because of its putative role in maintaining chromosome stability.
|
17187232 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eight different genes (Wnt1, Wnt3, Wnt10b, Fgf3, Fgf4, Fgf8, Int3, and Int6) have been shown to be genetically altered in multiple mammary tumors as a consequence of MMTV integration.
|
8738604 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several such genes int1/wnt1, wnt3, wnt 10B, int2/fgf3, fgf4, int3/notch and int6 have been shown to be genetically altered in naturally formed mammary tumors as a consequence of MMTV integration.
|
9334290 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, INT6/eIF3e is a double-edged sword that has both oncogenic and tumor suppressive abilities.
|
27814599 |
2017 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Taken together, our study data suggest that eIF3e has a positive role in breast cancer progression.
|
20453879 |
2010 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
In addition, EIF2S6/Int-6, which was originally identified as a common integration site for the mouse mammary tumour virus in virally induced mouse mammary tumours, is a candidate breast cancer susceptibility gene because of its putative role in maintaining chromosome stability.
|
17187232 |
2007 |
|
Breast Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
A reduced expression of Int-6/eIF3-p48 was seen in 23 (37%) of breast cancer samples and 24 (31%) of NSCLC samples.
|
11115556 |
2001 |
|
Breast Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
In addition, decreased expression of Int6/eIF3e is observed in approximately one third of all human breast carcinomas.
|
17626637 |
2007 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Our findings deepen insights into how INT6 protects against breast cancer by showing how it functions in DSB repair, with potential clinical implications for cancer therapy.
|
27550454 |
2016 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
We show that EMT induced by a decrease in eIF3e/Int6 expression imparts invasive and migratory properties to breast epithelial cells, suggesting that regulation of EMT by eIF3e/Int6 may have an important role in breast cancer metastasis.
|
22907435 |
2013 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas.
|
9403073 |
1997 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Loss of regulation of eIF3e/INT6 redistribution may therefore be a significant feature of malignancy in human cells.
|
15030549 |
2004 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Although a deeper understanding of the molecular mechanisms involved in these pathophysiological functions is essential, particularly to transform the <i>in vitro</i>/<i>in vivo</i> findings into clinical applications, INT6/eIF3e modulation could provide therapeutic benefit for a variety of human diseases such as cancer or vascular diseases.
|
27814599 |
2017 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
In this study we have examined Int-6/eIF3-p48 gene status and expression in two of the most common forms of cancer in humans, breast and lung tumors.
|
11115556 |
2001 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Altered expression of the eukaryotic translation initiation factor 3 (eIF3) subunit eIF3e/INT6 has been described in various types of human cancer, but the nature of its involvement in tumorigenesis is not yet clear.
|
20453879 |
2010 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Our findings deepen insights into how INT6 protects against breast cancer by showing how it functions in DSB repair, with potential clinical implications for cancer therapy.Cancer Res; 76(20); 6054-65.©2016 AACR.
|
27550454 |
2016 |